Apellis Forecasts Q4 Loss of $0.39 with Revenue Decline of 8.5%
Apellis Pharmaceuticals is projected to report a Q4 2025 loss of $0.39 per share, a 34.5% year-over-year decline, on revenues of $194.37 million, down 8.5%. The consensus EPS estimate rose 0.8% in the past month but a -3.07% Earnings ESP and a Zacks Rank #3 lower odds of a beat.
1. Q4 Earnings Forecast
Apellis Pharmaceuticals is expected to report a quarterly loss of $0.39 per share for Q4 2025, representing a 34.5% year-over-year increase in loss. Revenues are forecast at $194.37 million, marking an 8.5% decrease from the year-ago quarter.
2. Estimate Revisions and Earnings ESP
Consensus EPS estimates for the quarter have ticked 0.8% higher over the last 30 days. However, the Most Accurate Estimate sits below consensus, producing a -3.07% Earnings ESP, which, when paired with a Zacks Rank #3 (Hold), suggests limited visibility on an earnings beat.
3. Historical Surprise Record
Over the past four quarters, Apellis has surpassed consensus EPS estimates three times, indicating a generally positive track record despite mixed current signals from estimate revisions.